Lymphoma, T-Cell Clinical Trial
Official title:
A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma
Nasal NK/T-cell lymphoma is a peculiar clinico-pathologic subtype of non-Hodgkin's lymphoma
(NHL). Although most patients present with stage I/II, only 30-60% of the patients remain
disease-free. The efficacy of the conventional anthracycline-based chemotherapy
(cyclophosphamide, doxorubicin, vincristine, prednisone [CHOPP]) has been unsatisfactory.
The optimal treatment of localized NK/T-cell lymphoma has not been defined yet. The optimal
dose, sequence, and multi-modality treatment with involved field radiotherapy still need to
be refined. This trial is to evaluate the efficacy of concurrent chemoradiotherapy with
cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized
NK/T-cell lymphoma patients.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
| Completed |
NCT02158975 -
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
|
Phase 2 | |
| Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
| Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03703375 -
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
|
Phase 3 | |
| Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00038376 -
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
|
Phase 2 | |
| Recruiting |
NCT03161223 -
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05398614 -
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
| Completed |
NCT04121507 -
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
|
Phase 2 | |
| Completed |
NCT04136275 -
CAR-37 T Cells In Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03921879 -
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
|
Phase 1 | |
| Terminated |
NCT03154710 -
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
|
N/A | |
| Recruiting |
NCT05466318 -
ChiCGB vs BEAM in High-risk or R/R Lymphomas
|
Phase 3 | |
| Recruiting |
NCT04928105 -
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
|
N/A | |
| Withdrawn |
NCT04233697 -
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01309789 -
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
|
Phase 1 |